AUSTIN, Texas, October 14, 2025 — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will host a conference call and webcast on Thursday, Oct. 23, at 5:00 a.m. PT (8:00 a.m. ET) to discuss data in muscle-invasive bladder cancer that will be presented at the European Society for Medical Oncology (ESMO) Congress. This includes results from the randomized phase 3 IMvigor011 trial and from Checkmate 274.
Professor Thomas Powles, lead principal investigator of IMvigor011, Professor of Genitourinary Oncology, Chair of Barts Cancer Centre at St. Bartholomew’s Hospital, will join for the discussion.
Investor Conference Call Information
Event:
Natera Conference Call
Date:
October 23, 2025
Time:
5:00 a.m. PT (8:00 a.m. ET)
Live Dial-In:
1-888-770-7321 (Domestic)
1-929-201-7107 (International)
Conference ID:
7684785
Webcast:
https://events.q4inc.com/attendee/443911179